CClinicalTrials.gg
CompletedNCT05903443RBDDCUpdated Jun 15, 2023

Research on the Brain Death Determination in China

An observational study in Brain Death, Electroencephalogram and Evoked Potential, sponsored by Xuanwu Hospital, Beijing. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Xuanwu Hospital, Beijing · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,974
Ages
18 Years and older
Sex
All
01

Study summary

Purpose China has a population of 1.4 billion and an enormous medical expenditure burden, and Chinese traditional culture has a long history. It takes time to recognize and accept the concept of brain death (BD) as death. Promoting brain death determination (BDD) and rationally allocating medical resources have become major national policy issues. To identify the safest and most reliable ancillary tests needed if the clinical examination is incomplete.

Method The technical group of the Brain Injury Evaluation Quality Control Center of the National Health Commission retrieved coma cases registered from 2013 to 2019. According to clinical criteria for Brain Death Determination (BDD), the patients were divided into two groups: a brain-death (BD) group and a non-BD group. The BD group was divided into a complete brain death with no doubt group (BD1 group) and an incomplete brain death with doubt group (BD2 group). Depending on the site of the brain injury, the accuracy of BDD was evaluated using the independent ancillary test or combined ancillary tests. Data from the BQCC/NHC database and yearbook were obtained, and data analysis and status comparison were conducted on six practical activities: organizational system construction, standard and specification formulation, case quality control, professional skills training, scientific research publicity and education, and international communication.

02

Conditions studied

  • Brain Death
  • Electroencephalogram
  • Evoked Potential
  • TCD
  • Quality Control

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Coma cases registered by the National Brain Death Determination Quality Control Demonstration Hospital (BDQCH) in the BQCC/NHC from 2013 to 2019 were retrieved.

Inclusion criteria

  • All cases met the clinical criteria for BD, involving deep coma (Glasgow Coma Scale (GCS)=2T), the absence of brainstem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex), and spontaneous respiration. Ancillary tests were completed for all patients.

Exclusion criteria

Exclusion Criteria:

  • Does not meet BD clinical evaluation criteria. Ancillary tests were not implemented.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,974 participants (actual)
Patient registry
No

Groups and cohorts

  • BD group

    All cases met the (brain death) BD clinical evaluation criteria, which were as follows: the cause of coma was known; exclusion of reversible coma; deep coma, Glasgow coma scale (GCS) = 2T; absence of five brain stem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex); and no spontaneous respiration. Furthermore, according to whether the apnea test (AT) data were missing (implemented or completed), the patients were divided into the BD1 group (no AT missing group) and BD2 group (AT missing group).

    Diagnostic Test: ancillary tests

  • non-BD group

    All cases were from BDQCHs and fulfilled the criteria for coma (GCS of 3-5 points), but did not meet the clinical criteria for BD, such as retaining the brainstem reflex or having spontaneous respiration. For coma cases, all assessment items, specifications of technical operations, assessment steps, and evaluators were conducted in accordance with the requirements for BDD. Cases with coma were then submitted to the BQCC/NHC quality control system.

    Diagnostic Test: ancillary tests

Interventions

  • Diagnostic testancillary tests

    electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler

05

What researchers measure

Primary outcomes

  1. sensitivity

    The sensitivity of BDD was evaluated using the independent ancillary test and combined ancillary tests

    Time frame: 1 month

  2. specificity

    The specificity of BDD was evaluated using the independent ancillary test and combined ancillary tests

    Time frame: 1 month

06

Study locations

1 site
  • Xuanwu Hospital
    Beijing, Beijing 100053, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05903443
Lead sponsor
Xuanwu Hospital, Beijing
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Feb 1, 2023
Primary completion
Apr 15, 2023
Completion
May 15, 2023
Last update
Jun 15, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion